Kronostar 500 Tablet CR contains Sodium Valproate (333 mg) and Valproic Acid (145 mg), providing a combined dose of 500 mg of active ingredients in a controlled-release formulation. This medication is primarily indicated for the management of epilepsy, including generalized and partial seizures, as well as bipolar disorder and migraine prophylaxis. Sodium Valproate and Valproic Acid act by increasing the availability of gamma-aminobutyric acid (GABA) in the brain, thereby exerting an inhibitory effect on neuronal excitability and stabilizing mood. The controlled-release mechanism ensures a sustained therapeutic plasma concentration, reducing dosing frequency and enhancing patient compliance. Kronostar 500 Tablet CR should be administered under medical supervision, with dosage individualized according to clinical response and tolerability. Common adverse effects may include gastrointestinal disturbances, weight gain, tremor, and sedation; serious but less frequent risks involve hepatotoxicity, pancreatitis, and hematological abnormalities. Liver function tests and blood counts should be monitored regularly during therapy. This medication is contraindicated in patients with known hypersensitivity to valproate compounds, severe hepatic impairment, and urea cycle disorders. Caution is advised during pregnancy due to potential teratogenicity. Kronostar 500 Tablet CR is a valuable agent in the therapeutic arsenal for seizure control and mood stabilization, offering improved adherence through its controlled-release design.